{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:36:32Z","timestamp":1777534592714,"version":"3.51.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/cmi.2015.76","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T08:41:41Z","timestamp":1444034501000},"page":"36-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine"],"prefix":"10.1038","volume":"13","author":[{"given":"Huabin","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"BFcmi201576_CR1","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1038\/nm1144","volume":"10","author":"JS Mackenzie","year":"2004","unstructured":"Mackenzie JS, Gubler DJ, Petersen LR . Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10: S98\u2013S109.","journal-title":"Nat Med"},{"key":"BFcmi201576_CR2","unstructured":"World Health Organization. Yellow fever fact sheet No.100. [Updated March 2014]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs100\/en\/#."},{"key":"BFcmi201576_CR3","unstructured":"World Health Organization. Japanese encephalitis fact sheet No. 386. [Updated March 2014]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs386\/en\/."},{"key":"BFcmi201576_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature 2013; 496: 504\u2013507.","journal-title":"Nature"},{"key":"BFcmi201576_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0065-3527(03)60006-0","volume":"60","author":"LD Kramer","year":"2003","unstructured":"Kramer LD, Ebel GD . Dynamics of flavivirus infection in mosquitoes. Adv Virus Res 2003; 60: 187\u2013232.","journal-title":"Adv Virus Res"},{"key":"BFcmi201576_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.1979.28.119","volume":"28","author":"TH Aitken","year":"1979","unstructured":"Aitken TH, Tesh RB, Beaty BJ, Rosen L . Transovarial transmission of yellow fever virus by mosquitoes (Aedes aegypti). Am J Trop Med Hyg 1979; 28: 119\u2013121.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.203035","volume":"199","author":"L Rosen","year":"1978","unstructured":"Rosen L, Tesh RB, Lien JC, Cross JH . Transovarial transmission of Japanese encephalitis virus by mosquitoes. Science 1978; 199: 909\u2013911.","journal-title":"Science"},{"key":"BFcmi201576_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","volume":"44","author":"TJ Chambers","year":"1990","unstructured":"Chambers TJ, Hahn CS, Galler R, Rice CM . Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990; 44: 649\u2013688.","journal-title":"Annu Rev Microbiol"},{"key":"BFcmi201576_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1126\/science.4023707","volume":"229","author":"CM Rice","year":"1985","unstructured":"Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH . Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985; 229: 726\u2013733.","journal-title":"Science"},{"key":"BFcmi201576_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature02165","volume":"427","author":"Y Modis","year":"2004","unstructured":"Modis Y, Ogata S, Clements D, Harrison SC . Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427: 313\u2013319.","journal-title":"Nature"},{"key":"BFcmi201576_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","volume":"108","author":"RJ Kuhn","year":"2002","unstructured":"Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108: 717\u2013725.","journal-title":"Cell"},{"key":"BFcmi201576_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","volume":"29","author":"BR Murphy","year":"2011","unstructured":"Murphy BR, Whitehead SS . Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011; 29: 587\u2013619.","journal-title":"Annu Rev Immunol"},{"key":"BFcmi201576_CR13","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.1128\/JVI.73.11.9555-9567.1999","volume":"73","author":"JM Mackenzie","year":"1999","unstructured":"Mackenzie JM, Jones MK, Westaway EG . Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J Virol 1999; 73: 9555\u20139567.","journal-title":"J Virol"},{"key":"BFcmi201576_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/0042-6822(85)90446-5","volume":"140","author":"PW Chu","year":"1985","unstructured":"Chu PW, Westaway EG . Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virol 1985; 140: 68\u201379.","journal-title":"Virol"},{"key":"BFcmi201576_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/0022-1317-69-1-1","volume":"69","author":"G Coia","year":"1988","unstructured":"Coia G, Parker MD, Speight G, Byrne ME, Westaway EG . Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins. J Gen Virol 1988; 69: 1\u201321.","journal-title":"J Gen Virol"},{"key":"BFcmi201576_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1006\/viro.1998.9156","volume":"245","author":"JM Mackenzie","year":"1998","unstructured":"Mackenzie JM, Khromykh AA, Jones MK, Westaway EG . Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virol 1998; 245: 203\u2013215.","journal-title":"Virol"},{"key":"BFcmi201576_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/viro.1997.8629","volume":"234","author":"EG Westaway","year":"1997","unstructured":"Westaway EG, Khromykh AA, Kenney MT, Mackenzie JM, Jones MK . Proteins C and NS4B of the flavivirus Kunjin translocate independently into the nucleus. Virol 1997; 234: 31\u201341.","journal-title":"Virol"},{"key":"BFcmi201576_CR18","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1128\/jvi.71.9.6650-6661.1997","volume":"71","author":"EG Westaway","year":"1997","unstructured":"Westaway EG, Mackenzie JM, Kenney MT, Jones MK, Khromykh AA . Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997; 71: 6650\u20136661.","journal-title":"J Virol"},{"key":"BFcmi201576_CR19","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1128\/JVI.75.10.4633-4640.2001","volume":"75","author":"AA Khromykh","year":"2001","unstructured":"Khromykh AA, Varnavski AN, Sedlak PL, Westaway EG . Coupling between replication and packaging of flavivirus RNA: evidence derived from the use of DNA-based full-length cDNA clones of Kunjin virus. J Virol 2001; 75: 4633\u20134640.","journal-title":"J Virol"},{"key":"BFcmi201576_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0035-9203(53)90003-0","volume":"47","author":"FN Macnamara","year":"1953","unstructured":"Macnamara FN . Reactions following neurotropic yellow fever vaccine given by scarification in Nigeria. Trans R Soc Trop Med Hyg 1953; 47: 199\u2013208.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"BFcmi201576_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1084\/jem.65.6.767","volume":"65","author":"M Theiler","year":"1937","unstructured":"Theiler M, Smith HH . The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937; 65: 767\u2013786.","journal-title":"J Exp Med"},{"key":"BFcmi201576_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1084\/jem.65.6.787","volume":"65","author":"M Theiler","year":"1937","unstructured":"Theiler M, Smith HH . The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65: 787\u2013800.","journal-title":"J Exp Med"},{"key":"BFcmi201576_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri2629","volume":"9","author":"B Pulendran","year":"2009","unstructured":"Pulendran B . Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009; 9: 741\u2013747.","journal-title":"Nat Rev Immunol"},{"key":"BFcmi201576_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/imr.12099","volume":"255","author":"B Pulendran","year":"2013","unstructured":"Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA . Immunity to viruses: learning from successful human vaccines. Immunol Rev 2013; 255: 243\u2013255.","journal-title":"Immunol Rev"},{"key":"BFcmi201576_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","volume":"56","author":"B Reinhardt","year":"1998","unstructured":"Reinhardt B, Jaspert R, Niedrig M, Kostner C, L\u2019age-Stehr J . Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56: 159\u2013167.","journal-title":"J Med Virol"},{"key":"BFcmi201576_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4269\/ajtmh.2012.12-0179","volume":"88","author":"S Edupuganti","year":"2013","unstructured":"Edupuganti S, Eidex RB, Keyserling H, Akondy RS, Lanciotti R, Orenstein W et al. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. Am J Trop Med Hyg 2013; 88: 172\u2013177.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR27","first-page":"30","volume":"1","author":"BS Albert","year":"1952","unstructured":"Albert BS . Research on dengue during World War II. Arch Virol 1952; 1: 30\u201350.","journal-title":"Arch Virol"},{"key":"BFcmi201576_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jir439","volume":"204","author":"M Luiza-Silva","year":"2011","unstructured":"Luiza-Silva M, Campi-Azevedo AC, Batista MA, Martins MA, Avelar RS, Da Silveira Lemos D et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis 2011; 204: 873\u2013883.","journal-title":"J Infect Dis"},{"key":"BFcmi201576_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245\u2013252.","journal-title":"Nature"},{"key":"BFcmi201576_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"R Steinman","year":"2007","unstructured":"Steinman R, Banchereau J . Taking dendritic cells into medicine. Nature 2007; 449: 419\u2013426.","journal-title":"Nature"},{"key":"BFcmi201576_CR31","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.4049\/jimmunol.174.5.2457","volume":"174","author":"B Pulendran","year":"2005","unstructured":"Pulendran B . Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 2005; 174: 2457\u20132465.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10: 116\u2013125.","journal-title":"Nat Immunol"},{"key":"BFcmi201576_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1084\/jem.20051352","volume":"202","author":"G Barba-Spaeth","year":"2005","unstructured":"Barba-Spaeth G, Longman RS, Albert ML, Rice CM . Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005; 202: 1179\u20131184.","journal-title":"J Exp Med"},{"key":"BFcmi201576_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","volume":"203","author":"T Querec","year":"2006","unstructured":"Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203: 413\u2013424.","journal-title":"J Exp Med"},{"key":"BFcmi201576_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/ni712","volume":"2","author":"M Schnare","year":"2001","unstructured":"Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R . Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947\u2013950.","journal-title":"Nat Immunol"},{"key":"BFcmi201576_CR36","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.4049\/jimmunol.172.8.4733","volume":"172","author":"S Dillon","year":"2004","unstructured":"Dillon S, Agrawal A, Van Dyke T, Landreth G, Mccauley L, Koh A et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated proteinkinase and c-Fos in dendritic cells. J Immunol 2004; 172: 4733\u20134743.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR37","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.4049\/jimmunol.171.10.4984","volume":"171","author":"S Agrawal","year":"2003","unstructured":"Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171: 4984\u20134989.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR38","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1084\/jem.20082292","volume":"205","author":"D Gaucher","year":"2008","unstructured":"Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205: 3119\u20133131.","journal-title":"J Exp Med"},{"key":"BFcmi201576_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.cdd.4402170","volume":"15","author":"A Moretta","year":"2008","unstructured":"Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L . NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008; 15: 226\u2013233.","journal-title":"Cell Death Differ"},{"key":"BFcmi201576_CR40","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1016\/j.vaccine.2009.07.028","volume":"27","author":"PC Neves","year":"2009","unstructured":"Neves PC, Matos DC, Marcovistz R, Galler R . TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 2009; 27: 5543\u20135549.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.vaccine.2010.08.046","volume":"29","author":"ML Silva","year":"2011","unstructured":"Silva ML, Martins MA, Espirito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011; 29: 583\u2013592.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF01315703","volume":"76","author":"F Liprandi","year":"1983","unstructured":"Liprandi F, Walder R . Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). Arch Virol 1983; 76: 51\u201361.","journal-title":"Arch Virol"},{"key":"BFcmi201576_CR43","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.vaccine.2007.12.035","volume":"26","author":"MA Martins","year":"2008","unstructured":"Martins MA, Silva ML, Eloi-Santos SM, Ribeiro JG, Peruhype-Magalhaes V, Marciano AP et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 2008; 26: 1173\u20131184.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR44","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","volume":"168","author":"KU Belge","year":"2002","unstructured":"Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536\u20133542.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR45","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","volume":"183","author":"RS Akondy","year":"2009","unstructured":"Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183: 7919\u20137930.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR46","doi-asserted-by":"publisher","first-page":"e1938","DOI":"10.1371\/journal.pntd.0001938","volume":"7","author":"AB De Melo","year":"2013","unstructured":"De Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis 2013; 7: e1938.","journal-title":"PLoS Negl Trop Dis"},{"key":"BFcmi201576_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1006\/viro.2001.1255","volume":"293","author":"MD Co","year":"2002","unstructured":"Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL . Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 2002; 293: 151\u2013163.","journal-title":"Virology"},{"key":"BFcmi201576_CR48","doi-asserted-by":"publisher","first-page":"e718","DOI":"10.1111\/j.1365-2567.2009.03070.x","volume":"128","author":"MD Co","year":"2009","unstructured":"Co MD, Kilpatrick ED, Rothman AL . Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 2009; 128: e718\u2013e727.","journal-title":"Immunology"},{"key":"BFcmi201576_CR49","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller JD, Van Der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28: 710\u2013722.","journal-title":"Immunity"},{"key":"BFcmi201576_CR50","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.4049\/jimmunol.1202234","volume":"190","author":"K Blom","year":"2013","unstructured":"Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol 2013; 190: 2150\u20132158.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR51","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.4049\/jimmunol.1402605","volume":"194","author":"MR Bassi","year":"2015","unstructured":"Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjodt K et al. CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol 2015; 194: 1141\u20131153.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR52","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1128\/JVI.00036-15","volume":"89","author":"RM Zellweger","year":"2015","unstructured":"Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S . CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol 2015; 89: 6494\u20136505.","journal-title":"J Virol"},{"key":"BFcmi201576_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cyto.2008.02.007","volume":"42","author":"AP Santos","year":"2008","unstructured":"Santos AP, Matos DC, Bertho AL, Mendonca SC, Marcovistz R . Detection of Th1\/Th2 cytokine signatures in yellow fever 17DD first-time vaccines through ELISpot assay. Cytokine 2008; 42: 152\u2013155.","journal-title":"Cytokine"},{"key":"BFcmi201576_CR54","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/eji.201142306","volume":"42","author":"S Kohler","year":"2012","unstructured":"Kohler S, Bethke N, B\u00f6the M, Sommerick S, Frentsch M, Romagnani C et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol 2012; 42: 2363\u20132373.","journal-title":"Eur J Immunol"},{"key":"BFcmi201576_CR55","doi-asserted-by":"publisher","first-page":"12794","DOI":"10.1128\/JVI.01160-13","volume":"87","author":"EA James","year":"2013","unstructured":"James EA, Lafond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW . Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol 2013; 87: 12794\u201312804.","journal-title":"J Virol"},{"key":"BFcmi201576_CR56","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843\u2013850.","journal-title":"Nat Med"},{"key":"BFcmi201576_CR57","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","volume":"21","author":"AD Barrett","year":"2009","unstructured":"Barrett AD, Teuwen DE . Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 2009; 21: 308\u2013313.","journal-title":"Curr Opin Immunol"},{"key":"BFcmi201576_CR58","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1172\/JCI75429","volume":"124","author":"E Muyanja","year":"2014","unstructured":"Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 2014; 124: 3147\u20133158.","journal-title":"J Clin Invest"},{"key":"BFcmi201576_CR59","first-page":"895","volume":"59","author":"JD Poland","year":"1981","unstructured":"Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K . Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine. Bull World Health Org 1981; 59: 895\u2013900.","journal-title":"Bull World Health Org"},{"key":"BFcmi201576_CR60","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","volume":"67","author":"MW Brandriss","year":"1986","unstructured":"Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M . Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 1986; 67: 229\u2013234.","journal-title":"J Gen Virol"},{"key":"BFcmi201576_CR61","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1128\/jvi.60.3.1153-1155.1986","volume":"60","author":"JJ Schlesinger","year":"1986","unstructured":"Schlesinger JJ, Brandriss MW, Cropp CB, Monath TP . Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 1986; 60: 1153\u20131155.","journal-title":"J Virol"},{"key":"BFcmi201576_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2012.02.001","volume":"94","author":"BA Thibodeaux","year":"2012","unstructured":"Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129\/17D-204 peripheral challenge mouse model. Antiviral Res 2012; 94: 1\u20138.","journal-title":"Antiviral Res"},{"key":"BFcmi201576_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","volume":"64","author":"TP Monath","year":"2014","unstructured":"Monath TP, Vasconcelos PF . Yellow fever. J Clin Virol 2014; 64: 160\u201373","journal-title":"J Clin Virol"},{"key":"BFcmi201576_CR64","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","volume":"66","author":"TP Monath","year":"2002","unstructured":"Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-VAX) in a Phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66: 533\u2013541.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR65","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","volume":"29","author":"JG Julander","year":"2011","unstructured":"Julander JG, Trent DW, Monath TP . Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011; 29: 6008\u20136016.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR66","doi-asserted-by":"publisher","first-page":"748","DOI":"10.4269\/ajtmh.2011.11-0363","volume":"85","author":"A Kay","year":"2011","unstructured":"Kay A, Chen LH, Sisti M, Monath TP . Short report: yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg 2011; 85: 748\u2013749.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR67","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","volume":"24","author":"MJ Hepburn","year":"2006","unstructured":"Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006; 24: 2843\u20132849.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR68","first-page":"1056","volume":"79","author":"M Osei-Kwasi","year":"2001","unstructured":"Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK . Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Org 2001; 79: 1056\u20131059.","journal-title":"Bull World Health Org"},{"key":"BFcmi201576_CR69","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","volume":"60","author":"J Lang","year":"1999","unstructured":"Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C . Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999; 60: 1045\u20131050.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR70","first-page":"699","volume":"27","author":"H Groot","year":"1962","unstructured":"Groot H, Bahiarib. R . Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Org 1962; 27: 699\u2013707.","journal-title":"Bull World Health Org"},{"key":"BFcmi201576_CR71","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","volume":"32","author":"Vaccines","year":"2014","unstructured":"Vaccines. CGFSOYF. Duration of post-vaccination immunity against yellow fever in adults. Vaccine 2014; 32: 4977\u20134984.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR72","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","volume":"89","author":"E Gotuzzo","year":"2013","unstructured":"Gotuzzo E, Yactayo S, Cordova E . Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013; 89: 434\u2013444.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR73","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","volume":"4","author":"M Niedrig","year":"1999","unstructured":"Niedrig M, Lademann M, Emmerich P, Lafrenz M . Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999; 4: 867\u2013871.","journal-title":"Trop Med Int Health"},{"key":"BFcmi201576_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/oxfordjournals.aje.a121232","volume":"93","author":"TP Monath","year":"1971","unstructured":"Monath TP . Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 1971; 93: 122\u2013129.","journal-title":"Am J Epidemiol"},{"key":"BFcmi201576_CR75","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.4269\/ajtmh.2012.12-0182","volume":"87","author":"KB Gibney","year":"2012","unstructured":"Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS et al. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3\u20134 years following yellow fever vaccination. Am J Trop Med Hyg 2012; 87: 1112\u20131115.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcv.2012.08.024","volume":"55","author":"FX Heinz","year":"2012","unstructured":"Heinz FX, Stiasny K . Flaviviruses and their antigenic structure. J Clin Virol 2012; 55: 289\u2013295.","journal-title":"J Clin Virol"},{"key":"BFcmi201576_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","volume":"1","author":"TP Monath","year":"2001","unstructured":"Monath TP . Yellow fever: an update. Lancet Infect Dis 2001; 1: 11\u201320.","journal-title":"Lancet Infect Dis"},{"key":"BFcmi201576_CR78","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nm1240","volume":"11","author":"T Oliphant","year":"2005","unstructured":"Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11: 522\u2013530.","journal-title":"Nat Med"},{"key":"BFcmi201576_CR79","doi-asserted-by":"publisher","first-page":"13097","DOI":"10.1128\/JVI.76.24.13097-13100.2002","volume":"76","author":"DW Beasley","year":"2002","unstructured":"Beasley DW, Barrett AD . Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002; 76: 13097\u201313100.","journal-title":"J Virol"},{"key":"BFcmi201576_CR80","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1128\/JVI.00432-07","volume":"81","author":"S Sukupolvi-Petty","year":"2007","unstructured":"Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007; 81: 12816\u201312826.","journal-title":"J Virol"},{"key":"BFcmi201576_CR81","doi-asserted-by":"publisher","first-page":"e1003458","DOI":"10.1371\/journal.ppat.1003458","volume":"9","author":"O Vratskikh","year":"2013","unstructured":"Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 2013; 9: e1003458.","journal-title":"PLoS Pathog"},{"key":"BFcmi201576_CR82","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4049\/jimmunol.135.4.2805","volume":"135","author":"JJ Schlesinger","year":"1985","unstructured":"Schlesinger JJ, Brandriss MW, Walsh EE . Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein Gp48 and by active immunization with Gp48. J Immunol 1985; 135: 2805\u20132809.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR83","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1006\/viro.1993.1015","volume":"192","author":"JJ Schlesinger","year":"1993","unstructured":"Schlesinger JJ, Foltzer M, Chapman S . The Fc portion of antibody to yellow-fever virus-Ns1 is a determinant of protection against yellow fever encephalitis in mice. Virology 1993; 192: 132\u2013141.","journal-title":"Virology"},{"key":"BFcmi201576_CR84","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","volume":"4","author":"TC Pierson","year":"2008","unstructured":"Pierson TC, Fremont DH, Kuhn RJ, Diamond MS . Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008; 4: 229\u2013238.","journal-title":"Cell Host Microbe"},{"key":"BFcmi201576_CR85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4049\/jimmunol.99.2.291","volume":"99","author":"PK Russell","year":"1967","unstructured":"Russell PK, Nisalak A . Dengue virus identification by the plaque reduction neutralization test. J Immunol 1967; 99: 291\u2013296.","journal-title":"J Immunol"},{"key":"BFcmi201576_CR86","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.342.6157.415","volume":"342","author":"D Normile","year":"2013","unstructured":"Normile D . Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013; 342: 415.","journal-title":"Science"},{"key":"BFcmi201576_CR87","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","volume":"60","author":"SB Halstead","year":"2003","unstructured":"Halstead SB . Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60: 421\u2013467.","journal-title":"Adv Virus Res"},{"key":"BFcmi201576_CR88","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1099\/0022-1317-71-12-2909","volume":"71 (Pt12)","author":"DM Morens","year":"1990","unstructured":"Morens DM, Halstead SB . Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 1990; 71 (Pt12): 2909\u20132914.","journal-title":"J Gen Virol"},{"key":"BFcmi201576_CR89","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","volume":"158","author":"MG Guzman","year":"2013","unstructured":"Guzman MG, Alvarez M, Halstead SB . Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013; 158: 1445\u20131459.","journal-title":"Arch Virol"},{"key":"BFcmi201576_CR90","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","volume":"14","author":"JE Osorio","year":"2014","unstructured":"Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14: 830\u2013838.","journal-title":"Lancet Infect Dis"},{"key":"BFcmi201576_CR91","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","volume":"207","author":"AP Durbin","year":"2013","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013; 207: 957\u2013965.","journal-title":"J Infect Dis"},{"key":"BFcmi201576_CR92","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","volume":"29","author":"CG Beckett","year":"2011","unstructured":"Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011; 29: 960\u2013968.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR93","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","volume":"77","author":"CY Huang","year":"2003","unstructured":"Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM . Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003; 77: 11436\u201311447.","journal-title":"J Virol"},{"issue":"7","key":"BFcmi201576_CR94","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","volume":"212","author":"Sarah L. George","year":"2015","unstructured":"George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded Phase 1 clinical trial. J Infect Dis 2015; doi:10.1093\/infdis\/jiv179","journal-title":"Journal of Infectious Diseases"},{"key":"BFcmi201576_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/vim.2006.19.10","volume":"19","author":"JE Blaney","year":"2006","unstructured":"Blaney JE, Durbin AP, Murphy BR, Whitehead SS . Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006; 19: 10\u201332.","journal-title":"Viral Immunol"},{"key":"BFcmi201576_CR96","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/hv.2.6.3494","volume":"2","author":"AP Durbin","year":"2006","unstructured":"Durbin AP, Mcarthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K et al. rDEN2\/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-na\u00efve adults. Hum Vaccin 2006; 2: 255\u2013260.","journal-title":"Hum Vaccin"},{"key":"BFcmi201576_CR97","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","volume":"212","author":"BD Kirkpatrick","year":"2015","unstructured":"Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 2015; 212 (5):702\u2013710.","journal-title":"J Infect Dis"},{"key":"BFcmi201576_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4269\/ajtmh.2003.69.17","volume":"69","author":"N Kanesa-Thasan","year":"2003","unstructured":"Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69: 17\u201323.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR99","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","volume":"78","author":"S Simasathien","year":"2008","unstructured":"Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008; 78: 426\u2013433.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR100","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","volume":"85","author":"V Watanaveeradej","year":"2011","unstructured":"Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 2011; 85: 341\u2013351.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.13-0452","volume":"91","author":"V Watanaveeradej","year":"2014","unstructured":"Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A et al. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg 2014; 91: 119\u2013128.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR102","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384: 1358\u20131365.","journal-title":"Lancet"},{"key":"BFcmi201576_CR103","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","volume":"74","author":"F Guirakhoo","year":"2000","unstructured":"Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74: 5477\u20135485.","journal-title":"J Virol"},{"key":"BFcmi201576_CR104","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","volume":"75","author":"F Guirakhoo","year":"2001","unstructured":"Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001; 75: 7290\u20137304.","journal-title":"J Virol"},{"key":"BFcmi201576_CR105","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","volume":"380","author":"A Sabchareon","year":"2012","unstructured":"Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559\u20131567.","journal-title":"Lancet"},{"key":"BFcmi201576_CR106","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372: 113\u2013123.","journal-title":"N Engl J Med"},{"key":"BFcmi201576_CR107","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4269\/ajtmh.2007.76.144","volume":"76","author":"F Deauvieau","year":"2007","unstructured":"Deauvieau F, Sanchez V, Balas C, Kennel A, De Montfort A, Lang J et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1\u20134. Am J Trop Med Hyg 2007; 76: 144\u2013154.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR108","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","volume":"26","author":"B Guy","year":"2008","unstructured":"Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26: 5712\u20135721.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR109","doi-asserted-by":"publisher","first-page":"16922","DOI":"10.1073\/pnas.1010867107","volume":"107","author":"T Duangchinda","year":"2010","unstructured":"Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010; 107: 16922\u201316927.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcmi201576_CR110","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/infdis\/jir012","volume":"203","author":"S Hatch","year":"2011","unstructured":"Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203: 1282\u20131291.","journal-title":"J Infect Dis"},{"key":"BFcmi201576_CR111","doi-asserted-by":"publisher","first-page":"e1003723","DOI":"10.1371\/journal.ppat.1003723","volume":"9","author":"RM Zellweger","year":"2013","unstructured":"Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S . Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9: e1003723.","journal-title":"PLoS Pathog"},{"key":"BFcmi201576_CR112","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/JVI.02675-12","volume":"87","author":"L Rivino","year":"2013","unstructured":"Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013; 87: 2693\u20132706.","journal-title":"J Virol"},{"key":"BFcmi201576_CR113","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","volume":"29","author":"RZ Capeding","year":"2011","unstructured":"Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29: 3863\u20133872.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR114","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","volume":"89","author":"GH Dayan","year":"2013","unstructured":"Dayan GH, Garbes P, Noriega F, Izoton De Sadovsky AD, Rodrigues PM, Giuberti C et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil. Am J Trop Med Hyg 2013; 89: 1058\u20131065.","journal-title":"Am J Trop Med Hyg"},{"key":"BFcmi201576_CR115","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","volume":"30","author":"CF Lanata","year":"2012","unstructured":"Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B et al. Immunogenicity and safety of tetravalent dengue vaccine in 2\u201311 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012; 30: 5935\u20135941.","journal-title":"Vaccine"},{"key":"BFcmi201576_CR116","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","volume":"30","author":"J Poo","year":"2011","unstructured":"Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH . Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011; 30: e9\u2013e17.","journal-title":"Pediatr Infect Dis J"},{"key":"BFcmi201576_CR117","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4161\/hv.21224","volume":"8","author":"YS Leo","year":"2012","unstructured":"Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2\u201345 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012; 8: 1259\u20131271.","journal-title":"Hum Vaccin Immunother"},{"key":"BFcmi201576_CR118","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","volume":"68 (Pt3)","author":"JJ Schlesinger","year":"1987","unstructured":"Schlesinger JJ, Brandriss MW, Walsh EE . Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 1987; 68 (Pt3): 853\u2013857.","journal-title":"J Gen Virol"},{"key":"BFcmi201576_CR119","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1128\/jvi.64.9.4356-4363.1990","volume":"64","author":"B Falgout","year":"1990","unstructured":"Falgout B, Bray M, Schlesinger JJ, Lai CJ . Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 1990; 64: 4356\u20134363.","journal-title":"J Virol"},{"key":"BFcmi201576_CR120","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/500949","volume":"193","author":"P Avirutnan","year":"2006","unstructured":"Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193: 1078\u20131088.","journal-title":"J Infect Dis"},{"key":"BFcmi201576_CR121","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4161\/hv.2.2.2555","volume":"2","author":"F Guirakhoo","year":"2006","unstructured":"Guirakhoo F, Kitchener S, Morrison D, Forrat R, Mccarthy K, Nichols R et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVaxTM-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2: 60\u201367.","journal-title":"Hum Vaccin"},{"key":"BFcmi201576_CR122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/biol.1997.0056","volume":"25","author":"AD Barrett","year":"1997","unstructured":"Barrett AD . Yellow fever vaccines. Biologicals 1997; 25: 17\u201325.","journal-title":"Biologicals"},{"key":"BFcmi201576_CR123","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1006\/viro.1993.1090","volume":"192","author":"AD Jennings","year":"1992","unstructured":"Jennings AD, Whitby JE, Minor PD, Barrett ADT . Comparison of nucleotide and deduced amino acid sequences of the envelope protein genes of the wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French neurotropic vaccine, derived from it. Virology 1992; 192: 692\u2013695.","journal-title":"Virology"},{"key":"BFcmi201576_CR124","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","volume":"358","author":"M Martin","year":"2001","unstructured":"Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358: 98\u2013104.","journal-title":"Lancet"},{"key":"BFcmi201576_CR125","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/14760584.4.4.553","volume":"4","author":"TP Monath","year":"2005","unstructured":"Monath TP . Yellow fever vaccine. Expert Rev Vaccines 2005; 4: 553\u2013574.","journal-title":"Expert Rev Vaccines"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cmi201576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cmi201576","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cmi201576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T11:04:17Z","timestamp":1672743857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cmi201576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFcmi201576"],"URL":"https:\/\/doi.org\/10.1038\/cmi.2015.76","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]},"assertion":[{"value":"5 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}